---

---

tags : Presentation    crawled time : 16:20   

save search

---

Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023
Published: 2023-12-10 (Crawled : 16:20) - globenewswire.com
JSPR | $21.61 -6.89% -7.4% 65K |

| Email alert Add to watchlist
presentation positive cell aml therapeutics results study

---

Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023
Published: 2023-11-26 (Crawled : 16:20) - globenewswire.com
MRUS | $39.83 -1.58% -1.61% 800K |

Health Technology

| Email alert Add to watchlist
mcla-129 congress presentation publication asia

---

Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress
Published: 2023-06-17 (Crawled : 16:20) - globenewswire.com
VERA | $37.96 -3.85% -4.0% 1.4M |

Professional, Scientific, and T...

| Email alert Add to watchlist
association renal presentation origin positive week trial therapeutics results igan

---

Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid
Published: 2022-12-11 (Crawled : 16:20) - globenewswire.com
BLCM | $0.0748 381.28% 6.1K |

Health Technology

| Email alert Add to watchlist
t-cell presentation potential

---

Sutro Biopharma Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022
Published: 2022-12-10 (Crawled : 16:20) - globenewswire.com
STRO | $3.635 -3.58% -3.71% 520K |

Health Technology

| Email alert Add to watchlist
stro-002 biopharma aml program presentation

---

Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress™
Published: 2022-06-25 (Crawled : 16:20) - prnewswire.com
IONS | $40.64 -0.42% -0.42% 850K |

Health Technology

| Email alert Add to watchlist
treatment hepatitis liver presentation positive international phase 2b chronic hepatitis b

---

Milestone Pharmaceuticals Announces Presentation of Data from Phase 3 NODE-302 Study of Etripamil for the Treatment of PSVT
Published: 2022-04-30 (Crawled : 16:20) - prnewswire.com
MIST | $1.64 0.61% 0.61% 30K |

Health Technology

| Email alert Add to watchlist
node-302 treatment presentation milestone phase 3

---

Vaccinex, Inc. Announces Upcoming Presentation at the 2022 American Association for Cancer Research Meeting Updating the Phase 1b Segment of the KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Meta
Published: 2022-03-09 (Crawled : 16:20) - ir.vaccinex.com
VCNX | $4.8 -2.76% 7.9K |

Health Technology

| 345.87% | O: 1.83% H: 18.92% C: 17.12%
america ema phase 1b research presentation pepinemab phase 1 keytruda dating cancer vaccine phase 2b

---

Sana Biotechnology Presentations at 2021 ASH Annual Meeting Highlight Progress with Platforms and CAR T Cell Programs
Published: 2021-12-12 (Crawled : 16:20) - globenewswire.com
SANA | $7.605 -1.62% -1.64% 3.4M |

| Email alert Add to watchlist
technology presentation biotech iot platform t-cell

---

Jaguar Health Announces the Presentation of Findings from the Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients at San Antonio Breast Cancer Symposium (SABCS 2021)
Published: 2021-12-10 (Crawled : 16:20) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M |

Health Technology

| -88.06% | O: 5.22% H: 0.0% C: 0.0%
health phase 2 symposium sabcs presentation diarrhea therapy cancer breast cancer initiated crofelemer

---

Plus Therapeutics Announces Presentation of Data from the ReSPECT™-GBM Trial and Plans for Treating Pediatric Brain Cancer
Published: 2021-08-21 (Crawled : 16:20) - globenewswire.com
PSTV | $1.67 -1.27% -1.28% 25K |

Health Technology

| Email alert Add to watchlist
presentation cancer brain cancer trial train

---

Iridium To Present At June Investor Conferences
Published: 2021-05-29 (Crawled : 16:20) - prnewswire.com
IRDM | $27.4 5.14% 4.89% 1.6M |

Communications

| Email alert Add to watchlist
conference presentation

---

Relmada Therapeutics Announces Poster Presentations at the American Psychiatric Association Annual Meeting 2021
Published: 2021-05-01 (Crawled : 16:20) - prnewswire.com
RLMD | $4.0 -6.98% -7.5% 150K |

Health Technology

| Email alert Add to watchlist
presentation

---

Posters And Abstracts Presented at AACR 2021
Published: 2021-04-11 (Crawled : 16:20) - theratech.com
THTX | $1.29 -12.78% 8.1K |

Health Technology

| Email alert Add to watchlist
presentation

---

MacroGenics Announces Presentations at the 2021 AACR Annual Meeting
Published: 2021-04-10 (Crawled : 16:20) - globenewswire.com
MGNX | $15.62 -2.8% -2.88% 1M |

Health Technology

| Email alert Add to watchlist
presentation

---

Harpoon Therapeutics Announces Data from Poster Presentations at the AACR Annual Meeting 2021
Published: 2021-04-10 (Crawled : 16:20) - globenewswire.com
HARP | $23.01 0.07% 6.6M |

Health Technology

| Email alert Add to watchlist
presentation

---

NuCana Announces Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
Published: 2021-04-10 (Crawled : 16:20) - globenewswire.com
NCNA | $3.81 0.53% 0.52% 33K |

Health Technology

| Email alert Add to watchlist
presentation cancer research

---

New Clinical Responses for AGEN1181 Presented at AACR
Published: 2021-04-10 (Crawled : 16:20) - globenewswire.com
AGEN | $5.3 6.64% 6.23% 1.5M |

Health Technology

| Email alert Add to watchlist
presentation response

---

BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society's Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide
Published: 2021-03-20 (Crawled : 16:20) - investors.biomarin.com
BMRN | $88.68 -1.54% -1.57% 1.8M |

Health Technology

| Email alert Add to watchlist
presentation treatment drop endocrine children achondroplasia

---

Gainers vs Losers

67%

33%

Top 10 Gainers

---

Your saved searches

---